Associated Papers
Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.
Liu L et al.
Medcomm, 2025
41346570 (PubMed )
Supplement: MCO2-6-e70483-s002.xlsx › Tumour_cellularity
The spectrum of TP53 mutations in Rwandan patients with gastric cancer.
Nzitakera A et al.
Genes and Environment : the Official Journal of the Japanese Environmental Mutagen Society, 2024
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S et al.
Current Oncology (toronto, Ont.), 2022
35877212 (PubMed )
Supplement: curroncol-29-00352-s001.zip › LUNGS1_16_june_2022_supplemental_2_variants_no_code.pdf
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study.
Catherwood MA et al.
Frontiers in Oncology, 2022
35837095 (PubMed )
Supplement: Table_1.xlsx › Table_1
Mitochondria in human acute myeloid leukemia cell lines have ultrastructural alterations linked to deregulation of their respiratory profiles.
Mondet J et al.
Experimental Hematology, 2021
Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients.
Ke L et al.
Frontiers in Molecular Biosciences, 2021
The genomic landscape of Mongolian hepatocellular carcinoma.
Candia J et al.
Nature Communications, 2020
32873799 (PubMed )
Supplement: 41467_2020_18186_MOESM15_ESM.xlsx › Suppl_Data_13
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
30224644 (PubMed )
Supplement: NIHMS1501645-supplement-3.xlsx › Sheet1
A variant by any name: quantifying annotation discordance across tools and clinical databases.
Yen JL et al.
Genome Medicine, 2017
28122645 (PubMed )
Supplement: 13073_2016_396_MOESM1_ESM.xlsx › Table_S1
Select a paper to view details